EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeitOpen Access · CC BY 4.0

Efficacy and Safety of 125 I Seed Implantation in the Treatment of Pelvic Recurrent Cervical Cancer Following Radiotherapy: A Single‐Arm Meta‐Analysis of Chinese Patients

Yunxin Wang iD, Yuhong Ma, Lijuan Zou, Hongwei Lei, Yun Teng, Fuxiu Ye, Feng Zhang, Haichen Zhang

Cancer Reports · 2024

DOI: 10.1002/cnr2.2147 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Reports, 2024. Verfasst von Yunxin Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Iodine Radioisotopes, Neoplasm Recurrence, Local, Brachytherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the "Unveiling the Leader" projects of the Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The study aimed to assess the efficacy and safety of 125 I seed implantation in the treatment of pelvic recurrent cervical cancer following radiotherapy. This meta‐analysis was registered in PROSPERO. We looked up relevant studies in the databases of CNKI, Wanfang, CBM, PubMed, Embase, Cochrane Library, and Web of Science. The endpoint measures include the objective response rate, disease control rate, progression‐free survival, overall survival, and adverse events. Recent Fidings The meta‐analysis included six studies and a total of 246 patients. The pooled ORR of tumor response was 63%, and the DCR was 87%. The median PFS was 9.09 months, and the median OS was 13.46 months. The incidence of adverse events of Grade ≥III was 6%.

Conclusion

In conclusion, this meta‐analysis confirmed that 125 I seed implantation has a good local control rate and high safety in the treatment of pelvic recurrent cervical cancer following radiotherapy, and can be used as a remedial treatment for pelvic recurrent cervical cancer following radiotherapy to prolong the survival time of patients. Trial Registration PROSPERO: CRD42023423857

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsIodine RadioisotopesNeoplasm Recurrence, LocalBrachytherapyHumansFemaleChinaPelvic NeoplasmsEast Asian People

Stichwörter der Autor:innen

125Ibrachytherapymeta‐analysisradiotherapyrecurrent cervical cancer

Substanzen

Iodine RadioisotopesIodine-125

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.

ORCID-Profile: Yunxin Wang

Förderung

  • the "Unveiling the Leader" projects of the Liaoning Province

Zitieren

APA

Wang, Y., Ma, Y., Zou, L., Lei, H., Teng, Y., Ye, F., Zhang, F., & Zhang, H. (2024). Efficacy and Safety of 125 I Seed Implantation in the Treatment of Pelvic Recurrent Cervical Cancer Following Radiotherapy: A Single‐Arm Meta‐Analysis of Chinese Patients. Cancer Reports. https://doi.org/10.1002/cnr2.2147

Vancouver

Wang Y, Ma Y, Zou L, Lei H, Teng Y, Ye F, et al. Efficacy and Safety of 125 I Seed Implantation in the Treatment of Pelvic Recurrent Cervical Cancer Following Radiotherapy: A Single‐Arm Meta‐Analysis of Chinese Patients. Cancer Reports. 2024. doi:10.1002/cnr2.2147

BibTeX
@article{Wang2024,
  author = {Wang, Yunxin and Ma, Yuhong and Zou, Lijuan and Lei, Hongwei and Teng, Yun and Ye, Fuxiu and Zhang, Feng and Zhang, Haichen},
  title = {Efficacy and Safety of 125 I Seed Implantation in the Treatment of Pelvic Recurrent Cervical Cancer Following Radiotherapy: A Single‐Arm Meta‐Analysis of Chinese Patients},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.2147}
}
Kostenlos starten →